title: Epstein-Barr virus: an important vaccine target for cancer prevention.
abstract: Participants at the February 2011 meeting at the U.S. National Institutes of Health on Epstein-Barr virus (EBV) vaccine research recommend that future clinical trials have two goals: prevention of infectious mononucleosis and EBV-associated cancers, facilitated by identification of disease-predictive surrogate markers.
authors: National Institute of Allergy and Infectious Diseases (NIAID), U.S. National Institutes of Health (NIH), Bethesda, MD 20892, USA. jcohen@niaid.nih.gov
authors: Jeffrey I
authors: JI
authors: Cohen
authors: Anthony S
authors: AS
authors: Fauci
authors: Harold
authors: H
authors: Varmus
authors: Gary J
authors: GJ
authors: Nabel
mesh_terms: D015415:Biomarkers / Q000032:analysis; D003226:Congresses as Topic; D020031:Epstein-Barr Virus Infections / Q000150:complications / Q000175:diagnosis / Q000517:prevention & control; D004854:Herpesvirus 4, Human / Q000472:pathogenicity*; D006801:Humans; D007244:Infectious Mononucleosis / Q000175:diagnosis / Q000517:prevention & control; D009369:Neoplasms / Q000517:prevention & control* / Q000821:virology*; D014765:Viral Vaccines / Q000627:therapeutic use*
chemical_list: D015415:Biomarkers; D014765:Viral Vaccines